Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 13/20 | 0.51 |
| ▸ | F10 | P00742 | 8/20 | 0.51 |
| ▸ | TMPRSS6 | Q8IU80 | 11/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4687769 | 0.93 | F10 (0.47) | F2F10TMPRSS6 | |
| Trifluoroacetic Acid SCHEMBL4680876 | 0.91 | F10 (0.52) | F2F10 | |
| Trifluoroacetic Acid SCHEMBL4687004 | 0.89 | F10 (0.51) | F2F10TMPRSS6ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL4681672 | 0.86 | F10 (0.48) | F2F10 | |
| Trifluoroacetic Acid SCHEMBL4681058 | 0.85 | F10 (0.51) | F2F10ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL4682216 | 0.85 | F10 (0.48) | F2F10 | |
| Trifluoroacetic Acid SCHEMBL4685323 | 0.84 | F10 (0.48) | F2F10ITGB3ITGA2B | |
| Trifluoroacetic Acid SCHEMBL4687645 | 0.84 | F10 (0.47) | F2F10 | |
| Trifluoroacetic Acid SCHEMBL4685963 | 0.84 | F10 (0.49) | F2F10 | |
| Trifluoroacetic Acid SCHEMBL3900443 | 0.84 | F10 (0.65) | F2F10ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1236712-B1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | AJINOMOTO KK (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-6710056-B2 | PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF HAVE AN EXCELLENT ANTAGONISTIC EFFECT AGAINST ACTIVATED BLOOD COAGULATION FACTOR VII. | AJINOMOTO CO., INC. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | AJINOMOTO CO. INC (JP) | 2003-06-12 | — | — | US | disclosed |
| EP-1236712-A1 | AMIDINOPHENYLPYRUVIC ACID DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109547-A1 | Amidinophenylpyruvic acid derivatives | HABP2, F2, F7 | F2 2/4885F10 26/4885TMPRSS6 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.